ASM News:Missling's 3-D chess strategy for 273
Missling likes the idea of accelerated approval for 273 if PDD, Alz results are good (which I interpret as they will try for it) but cautioned that because the markets for these drugs are so huge, they may require a P3.
Licensing will occur after the results of the 3 trials. BP will pay BIG money if results are promising. Licensing now would be selling out cheap
Rett was chosen in part because it has seizures as one of its symptoms. Seizure reduction will be used to plan for epilepsy.
Biomarkers idea came out of Missling's experience with cancer drugs, we are the first to use it for CNS. Same biomarkers are being applied for all tests.
Licensing for 273 could be by geography. Missling will weigh options for best deal for shareholders.
Rett we know the patients, could develop our own sales force and keep all the profits.
Trust the PLAN
Secretariat at the Belmont
News 
Market Data 
Discover 
